Company Overview - Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for cancer treatment [2] - The company aims to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to create next-generation cancer cell-targeting treatments, enhancing efficacy and safety by reducing off-target effects [2] Product Pipeline - The company's lead assets include iopofosine I 131, designed for targeted delivery of iodine-131 (radioisotope), CLR 121225 targeting solid tumors like pancreatic cancer, and CLR 121125 aimed at other solid tumors such as triple negative breast, lung, and colorectal cancers [3] - iopofosine I 131 has been studied in Phase 2b trials for relapsed or refractory multiple myeloma and CNS lymphoma, and is part of the CLOVER-2 Phase 1b study for pediatric patients with high-grade gliomas [4] - The FDA has granted iopofosine I 131 six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations for various cancer indications [4] Upcoming Events - Members of Cellectar's management team will present an overview of the company at the 37th Annual Roth Conference on March 17, 2025, at 8:30 AM Eastern Time [1]
Cellectar Biosciences to Present at the 37th Annual Roth Conference